A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose. npj Vaccines. 2024; 9:255.
.Intranasal parainfluenza virus type 5 (PIV5)-vectored RSV vaccine is safe and immunogenic in healthy adults in a phase 1 clinical study. Science Advances. 2023; 9:eadj7611.
.2023; 210:71.33.
. Ebola virus protein VP40 induces accessory cell-mediated activation of human natural killer (NK) cells. Journal of immunology (Baltimore, Md. : 1950).Ebola virus protein VP40 stimulates IL-12- and IL-18-dependent activation of human natural killer cells. JCI insight. 2022; 7:e158902.
.Parainfluenza Virus 5 Priming Followed by SIV/HIV Virus-Like-Particle Boosting Induces Potent and Durable Immune Responses in Nonhuman Primates. Frontiers in Immunology. 2021; 12:623996.
.